European Primary Care Cardiovascular Society

ESC 2020

EPCCS reports on studies presented at the digital ESC 2020. Find coverage of the latest CV news on IPCCS.org.

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD
Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

SGLT2i provides nephroprotective effects in CKD patients

3' education - Sep. 16, 2020 - Prof. Hiddo Heerspink, PhD
After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.

Improved outcomes with early rhythm control in AF

3' education - Sep. 16, 2020 - Prof. Paulus Kirchhof, MD
Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.

ESC 2020 Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.

Colchicine reduces CV death and ischemic events in chronic coronary disease

News - Sep. 9, 2020

ESC 2020 Colchicine reduced the risk of CV death, MI, ischemic stroke, or ischemia-driven coronary revascularization in patients with chronic coronary disease, compared to placebo.

Continuing versus suspending ACEi and ARBs in COVID-19

News - Sep. 9, 2020

ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.

Risk of major CV events reduced by BP lowering regardless of CVD status and baseline SBP

News - Sep. 9, 2020

ESC 2020 Blood pressure-lowering reduces the risk of major CV events similarly in those with and without CVD and irrespectively of baseline SBP.

Risk reduction for CV death or HF hospitalization with another SGLT2i in HFrEF

News - Sep. 9, 2020

ESC 2020 The EMPEROR-Reduced trial showed that empagliflozin reduced the risk of CV death or HF hospitalization by 25% in HFrEF patients with or without diabetes, compared to placebo.

In CKD, SGLT2i reduces risk of kidney failure, CV death or HF hospitalization, and all-cause mortality

News - Sep. 8, 2020

ESC 2020 The DAPA-CKD trial showed that dapagliflozin significantly reduced the risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in patients with CKD, with and without T2DM, compared to placebo.

Early rhythm control in patients with recently diagnosed AF provides benefit

News - Sep. 8, 2020

ESC 2020 The EAST-AFNET4 trial showed that patients with early AF and CV conditions benefit from early rhythm control therapy compared to patients who received standard therapy.